Why the study?
Does rivaroxaban reduce venous thromboembolism in acutely ill medical patients compared to enoxaparin?
Does rivaroxaban reduce venous thromboembolism in acutely ill medical patients compared to enoxaparin?
Extended-duration rivaroxaban reduces VTE risk in acutely ill medical patients but is associated with an increased risk of bleeding.
Answers are grounded in this paper and cite their sources.
Extended rivaroxaban may be considered for selected high-risk medical patients despite bleeding trade-off; extends RCT evidence on post-discharge thromboprophylaxis duration.
In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: